Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Sunesis Pharmaceuticals"
Count: 17
Selected: 0
NCT IDTitle
NCT03037645Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
NCT00252382Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
NCT01191801Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
NCT00298896Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
NCT00541866Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
NCT00408603Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
NCT00607997Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
NCT00446342Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
NCT00519662Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
NCT00246662Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
NCT00292864Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
NCT00094159Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
NCT00091585Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
NCT01913951Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
NCT01893320Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
NCT03338348Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
NCT01980056Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy